Zeposia® (ozanimod; Bristol Myers Squibb) is now available for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
This slideshow shows drug information for Xcopri. Click here for the complete Xcopri monograph. For a downloadable version of this slideshow, click here.
The FDA has approved updated labeling for Rebif® (has approved updated labeling for Rebif® (interferon beta-1a; EMD Serono) to include the addition of new safety data on pregnancy and lactation.interferon beta-1a; EMD Serono) to include the addition of new safety data on pregnancy and lactation.
Treatment with ofatumumab (Novartis) was associated with a greater proportion of patients with relapsing forms of multiple sclerosis (RMS) achieving no evidence of disease activity (NEDA-3), compared with those who received teriflunomide, according to post hoc analysis of the phase 3 ASCLEPIOS trials.
Positive topline data was announced from the phase 3 ADAPT trial of efgartigimod (ARG-113; argenx) in adult patients with generalized myasthenia gravis (gMG).
The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.
The FDA has granted Fast Track designation to arimoclomol (Orphazyme A/S) for the treatment of amyotrophic lateral sclerosis.
The Food and Drug Administration (FDA) has approved Kynmobi™ (apomorphine hydrochloride; Sunovion) for the acute, intermittent treatment of off episodes in patients with Parkinson disease (PD).
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
SK Life Science has announced the availability of Xcopri (cenobamate) tablets for the treatment of partial-onset seizures in adults.
